乳房缩小整形标本病理评估推荐:系统性取材的前瞻性研究
该前瞻性研究纳入2006至2013年单中心595例乳房缩小整形标本,在常规评估后行系统性补充取材,发现显著病理发现发生率为9.8%,癌发生率为2.4%,40岁以下未见癌,术前钼靶未检出癌或不典型增生,建议35岁以下仅行大体评估,40岁以上需增加取材。
要点
- 595例中显著病理发现(癌及不典型增生)发生率为9.8%。
- 癌总发生率为2.4%,40岁及以上为3.6%,50岁及以上为4.3%。
- 40岁以下未见癌,35岁以下仅大体评估即可,40岁以上建议增加取材。
核心结论
- 35岁以下患者仅大体评估足够,40岁以上患者可能需要增加取材。
研究设计与样本
- 单中心前瞻性研究,纳入2006至2013年所有乳房缩小整形标本共595例,基线大体和镜下评估后行系统性补充取材。
主要发现
- 显著病理发现(癌及不典型增生)在9.8%(58/595)的患者中存在。
- 癌发生率在所有患者中为2.4%(14/595),40岁及以上为3.6%(14/392),50岁及以上为4.3%(10/233)。
- 40岁以下患者未发现癌。
- 术前钼靶未发现癌或不典型增生。
- 增加取材仅与40岁及以上患者显著病理发现频率增加相关。
关键数值与推荐
- 35岁以下患者仅大体评估即可。
- 40岁以上患者可能需要增加取材。
临床怎么用
- 对乳房缩小整形标本,根据年龄选择取材策略:35岁以下可仅大体评估,40岁以上考虑增加取材。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: - Breast reduction mammaplasty (RMP) for symptomatic macromastia or correction of asymmetry is performed in more than 100 000 patients per year in the United States. The reported incidence of significant pathologic findings (SPF), that is, carcinoma and atypical hyperplasia, ranges from 0.06% to 12.8%. No standard pathology assessment for RMP exists. OBJECTIVES: - To propose standard sampling for microscopic evaluation in RMP specimens, to evaluate the incidence of occult carcinoma and atypical hyperplasia, and to identify clinical risk factors for SPF in patients undergoing RMP. DESIGN: - All RMP specimens from 2006 to 2013 at a single institution were prospectively examined. After baseline gross and microscopic evaluations, each specimen was subjected to systematic additional sampling. The incidence of SPF was tabulated, and variables such as age, specimen weight, previous history of SPF, and results of preoperative mammogram were examined. Clinical follow-up review was also subsequently undertaken. RESULTS: - A total of 595 patients were evaluated. Significant pathologic findings were present in 9.8% (58 of 595) of patients. No cancer was identified in patients younger than 40 years; the rates of carcinoma were 2.4% (14 of 595) in all patients, 3.6% (14 of 392) in patients aged 40 years or older, and 4.3% (10 of 233) in patients aged 50 years or older. No carcinoma or atypical hyperplasia was identified on preoperative mammogram. Increased sampling was associated with a significantly greater frequency of SPF only in patients aged 40 years or older. CONCLUSIONS: - In patients younger than 35 years, gross-only evaluation is sufficient. However, increased sampling may be necessary in patients older than 40 years.
引用
- Ambaye AB, Goodwin AJ, MacLennan SE, et al. Recommendations for Pathologic Evaluation of Reduction Mammoplasty Specimens: A Prospective Study With Systematic Tissue Sampling. Arch Pathol Lab Med. 2017. PMID: 28795842. doi:10.5858/arpa.2016-0492-OA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。